Form 4 for ONC BeOne Medicines Ltd.
Accepted 2024-12-17 00:00:00 ET · period of report 2024-12-14 · accession 0001651308-24-000167 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-17 | 2024-12-14 | ONC | OYLER JOHN | CEO, Dir | M - OptEx | $0.5 | +1.30M | 2.98M | +77% | +$650.0K |
| D | 2024-12-17 | 2024-12-14 | ONC | OYLER JOHN | CEO, Dir | M - OptEx | $0.00 | -1.30M | 10.10M | -11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-12-14 | M | A | 1,300,000 | $0.5 | 2,978,833 | D | — | — | |
| 2 | Derivative | Share Option (Right to Buy) | 2024-12-14 | M | D | 1,300,000 | $0.00 | 10,100,500 | D | $0.5 · — to 2025-07-19 | 1,300,000 Ordinary Shares | (F7) These securities vest over a five-year period as follows: 20% on July 19, 2016, and the remaining in 48 successive equal monthly installments, subject to continued service. |